Telbivudine
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| 1-(2-deoxy-β-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione | |
| Clinical data | |
| Trade names | Tyzeka |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a607045 |
| Licence data | EMA:Link, US FDA:link |
| Pregnancy cat. | B (US) |
| Legal status | POM (UK) ℞-only (US) |
| Routes | Oral |
| Pharmacokinetic data | |
| Protein binding | Low (3.3% in vitro) |
| Metabolism | Nil |
| Half-life | 40 to 49 hours (terminal phase) |
| Excretion | Renal |
| Identifiers | |
| CAS number | 3424-98-4  |
| ATC code | J05AF11 |
| PubChem | CID 159269 |
| DrugBank | DB01265 |
| ChemSpider | 140081 |
| UNII | 2OC4HKD3SF |
| ChEMBL | CHEMBL374731  |
| Synonyms | 1-(2-deoxy-β-L-ribofuranosyl)-5-methyluracil β-L-2-deoxythymidine β-L-thymidine (LdT) 1-[(2S,4R,5S)-4-hydroxy-5-hydroxymethyltetrahydrofuran-2-yl]-5-methyl-1H-pyrimidine-2,4-dione |
| Chemical data | |
| Formula | C10H14N2O5 |
| Mol. mass | 242.23 g/mol |
| SMILES
| |
| |
| (what is this?) (verify) | |
Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.[1][2][3]
Telbivudine is a synthetic thymidine nucleoside analogue; it is the L-isomer of thymidine. It is taken once daily.
References
- ↑ Lai CL, Leung N, Teo EK, et al. (2005). "A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B". Gastroenterology 129 (2): 528–36. doi:10.1016/j.gastro.2005.05.053. PMID 16083710.
- ↑ Lai CL, Gane E, Liaw YF, et al. (2007). "Telbivudine versus lamivudine in patients with chronic hepatitis B". N Engl J Med 357 (25): 2576–88. doi:10.1056/NEJMoa066422. PMID 18094378.
- ↑ Chan HL, Heathcote EJ, Marcellin P, et al. (4 December 2007). "Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial". Ann Intern Med 147 (11): 745–54. PMID 17909201.
External links
- Tyzeka official website run by Novartis Pharmaceuticals Corporation
- Telbivudine entry in RxList
- Sebivo Summary of Product Characteristics (from the EMEA website)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.